Urogen Pharma (NASDAQ:URGN) has been given a $62.00 price target by stock analysts at Oppenheimer in a research report issued to clients and investors on Thursday, March 15th. The brokerage presently has a “buy” rating on the stock. Oppenheimer’s price objective would suggest a potential upside of 4.94% from the stock’s previous close.
A number of other equities analysts also recently commented on URGN. Cowen restated a “buy” rating on shares of Urogen Pharma in a research note on Wednesday, November 15th. UBS cut Urogen Pharma from an “outperform” rating to a “market perform” rating in a report on Wednesday, November 15th. Raymond James Financial cut Urogen Pharma from an “outperform” rating to a “market perform” rating in a report on Wednesday, November 15th. CIBC reissued an “outperform” rating and set a $51.00 target price (up previously from $32.00) on shares of Urogen Pharma in a report on Wednesday, November 15th. Finally, Ladenburg Thalmann initiated coverage on Urogen Pharma in a report on Tuesday, January 2nd. They set a “buy” rating and a $50.00 target price on the stock. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $45.50.
NASDAQ:URGN traded down $0.48 during mid-day trading on Thursday, reaching $59.08. The stock had a trading volume of 202,068 shares, compared to its average volume of 131,533. The company has a market capitalization of $812.41 and a price-to-earnings ratio of -27.61. Urogen Pharma has a 1-year low of $13.01 and a 1-year high of $65.89.
Urogen Pharma (NASDAQ:URGN) last issued its earnings results on Thursday, March 15th. The company reported ($0.74) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.65) by ($0.09). The business had revenue of $0.33 million during the quarter. analysts expect that Urogen Pharma will post -3.26 earnings per share for the current fiscal year.
A number of institutional investors have recently bought and sold shares of URGN. Meitav Dash Investments Ltd. purchased a new position in Urogen Pharma during the 4th quarter worth approximately $15,363,000. Lyon Street Capital LLC grew its position in Urogen Pharma by 35.6% during the 4th quarter. Lyon Street Capital LLC now owns 56,617 shares of the company’s stock worth $2,107,000 after purchasing an additional 14,876 shares in the last quarter. Millennium Management LLC purchased a new position in Urogen Pharma during the 4th quarter worth approximately $427,000. Bainco International Investors grew its position in Urogen Pharma by 44.9% during the 4th quarter. Bainco International Investors now owns 104,961 shares of the company’s stock worth $5,204,000 after purchasing an additional 32,500 shares in the last quarter. Finally, Two Sigma Investments LP purchased a new position in Urogen Pharma during the 4th quarter worth approximately $277,000. Hedge funds and other institutional investors own 50.49% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Urogen Pharma (URGN) Given a $62.00 Price Target by Oppenheimer Analysts” was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this article on another website, it was stolen and republished in violation of US & international copyright and trademark laws. The original version of this article can be read at https://www.dispatchtribunal.com/2018/04/08/urogen-pharma-urgn-pt-set-at-62-00-by-oppenheimer.html.
Urogen Pharma Company Profile
Urogen Pharma Ltd, formerly Theracoat Ltd, is an Israel-based clinical-stage biopharmaceutical company. It is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract.
Receive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.